finanzen.net

AMGEN --- kaufen ....

Seite 1 von 1
neuester Beitrag: 04.01.07 18:17
eröffnet am: 26.07.06 18:51 von: Niraznaz Anzahl Beiträge: 6
neuester Beitrag: 04.01.07 18:17 von: charly2 Leser gesamt: 7781
davon Heute: 4
bewertet mit 2 Sternen

26.07.06 18:51
2

287 Postings, 6901 Tage NiraznazAMGEN --- kaufen ....

Amgen sieht gut aus nach den Zahlen.
Schaut Euch mal den Schein der Commerzbank an:
CB2863
Um ein Drittel billiger als die Konkurrenz....CG13PV und GS0GB5

Die haben die Vola ca. 2% niedriger. Wird bestimmt bald nach oben angepasst!

Meinungen ???  

26.07.06 19:44

287 Postings, 6901 Tage Niraznazup

up  

26.07.06 21:09

7981 Postings, 6013 Tage hotte39CB2863 CG13PV GS0GB5

Ein Drittel billiger?
Müssen wir mal verfolgen!

(Leider funzt bei mir die Ariva-Anzeige nicht! Weiß jemand warum?).  

27.07.06 17:32

287 Postings, 6901 Tage Niraznazund???

Keiner ne MEinung ?  

14.11.06 12:58

5127 Postings, 5836 Tage Steff23Kaufen: Meine Meinung!

Amgen arthritis drug shows sustained safety and efficacy
13th November 2006

By Victoria Harrison
Amgen has said that its product Enbrel has showed improvements in multiple measures of efficacy that were sustained in rheumatoid arthritis patients completing up to nine years of therapy.
Enbrel showed strong safety profile for extended periods of use. In the studies, rates of serious adverse events and serious infections remained low. The numbers of observed malignancies, excluding non-melanoma skin cancers, were similar in type and number to what would be expected in the general population.


AdvertisementAdditionally, data showed that 77 early rheumatoid arthritis (ERA) and 280 long-standing rheumatoid arthritis (LRA) patients who completed Enbrel treatment for up to eight years experienced substantial improvements in their ACR scores. Additionally, 73 LRA patients who completed Enbrel treatment for up to nine years experienced similar improvements. ACR scores are a composite measure of improvement in rheumatoid arthritis symptoms, including joint swelling and tenderness, pain, level of disability, overall patient and physician assessment, and an objective marker of inflammation.

The ability to perform daily activities was also improved upon treatment with Enbrel may help them achieve this goal. Through eight years of treatment with Enbrel, data showed that 73 to 85% of patients with ERA and 53 to 72% of patients with LRA achieved a clinically significant improvement in the Health Assessment Questionnaire score, a patient questionnaire that measures disability.

These studies were designed to assess the safety and long-term efficacy of Enbrel in adult LRA patients who have failed to respond to at least one disease-modifying antirheumatic drug, and adult patients with ERA.  

04.01.07 18:17

6576 Postings, 5061 Tage charly2Amgen hat Nachholbedarf

Amgen outperform
Donnerstag, 04. Jänner 2007
 

Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Bear Stearns stufen die Aktie von Amgen (ISIN US0311621009/ WKN 867900) von "peer perform" auf "outperform" hoch. (04.01.2007/ac/a/u)
Analyse-Datum: 04.01.2007  

 

   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
TeslaA1CX3T
NEL ASAA0B733
PowerCell Sweden ABA14TK6
Ballard Power Inc.A0RENB
Apple Inc.865985
Varta AGA0TGJ5
Deutsche Bank AG514000
Daimler AG710000
Microsoft Corp.870747
CommerzbankCBK100
BASFBASF11
SteinhoffA14XB9
ITM Power plcA0B57L
Deutsche Telekom AG555750